Research ExplorerPublicationsEvaluation of Immunophenotypic and Molecular Biomarkers for ...

Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures

Standard

Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures : A Multicenter Study of 59 Patients. / Boonk, Stephanie E; Zoutman, Willem H; Marie-Cardine, Anne; van der Fits, Leslie; Out-Luiting, Jacoba J; Mitchell, Tracey J; Tosi, Isabella; Morris, Stephen L; Moriarty, Blaithin; Booken, Nina; Felcht, Moritz; Quaglino, Pietro; Ponti, Renata; Barberio, Emanuela; Ram-Wolff, Caroline; Jäntti, Kirsi; Ranki, Annamari; Bernengo, Maria Grazia; Klemke, Claus-Detlev; Bensussan, Armand; Michel, Laurence; Whittaker, Sean; Bagot, Martine; Tensen, Cornelis P; Willemze, Rein; Vermeer, Maarten H.

In: J INVEST DERMATOL, Vol. 136, No. 7, 07.2016, p. 1364-1372.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Boonk, SE, Zoutman, WH, Marie-Cardine, A, van der Fits, L, Out-Luiting, JJ, Mitchell, TJ, Tosi, I, Morris, SL, Moriarty, B, Booken, N, Felcht, M, Quaglino, P, Ponti, R, Barberio, E, Ram-Wolff, C, Jäntti, K, Ranki, A, Bernengo, MG, Klemke, C-D, Bensussan, A, Michel, L, Whittaker, S, Bagot, M, Tensen, CP, Willemze, R & Vermeer, MH 2016, 'Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients', J INVEST DERMATOL, vol. 136, no. 7, pp. 1364-1372. https://doi.org/10.1016/j.jid.2016.01.038

APA

Boonk, S. E., Zoutman, W. H., Marie-Cardine, A., van der Fits, L., Out-Luiting, J. J., Mitchell, T. J., Tosi, I., Morris, S. L., Moriarty, B., Booken, N., Felcht, M., Quaglino, P., Ponti, R., Barberio, E., Ram-Wolff, C., Jäntti, K., Ranki, A., Bernengo, M. G., Klemke, C-D., ... Vermeer, M. H. (2016). Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. J INVEST DERMATOL, 136(7), 1364-1372. https://doi.org/10.1016/j.jid.2016.01.038

Vancouver

Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ et al. Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. J INVEST DERMATOL. 2016 Jul;136(7):1364-1372. https://doi.org/10.1016/j.jid.2016.01.038

Bibtex

@article{856d2c7de6ee4a189014264fbe806009,
title = "Evaluation of Immunophenotypic and Molecular Biomarkers for S{\'e}zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients",
abstract = "Differentiation between S{\'e}zary syndrome and erythrodermic inflammatory dermatoses can be challenging, and a number of studies have attempted to identify characteristic immunophenotypic changes and molecular biomarkers in S{\'e}zary cells that could be useful as additional diagnostic criteria. In this European multicenter study, the sensitivity and specificity of these immunophenotypic and recently proposed but unconfirmed molecular biomarkers in S{\'e}zary syndrome were investigated. Peripheral blood CD4(+) T cells from 59 patients with S{\'e}zary syndrome and 19 patients with erythrodermic inflammatory dermatoses were analyzed for cell surface proteins by flow cytometry and for copy number alterations and differential gene expression using custom-made quantitative PCR plates. Experiments were performed in duplicate in two independent centers using standard operating procedures with almost identical results. S{\'e}zary cells showed MYC gain (40%) and MNT loss (66%); up-regulation of DNM3 (75%), TWIST1 (69%), EPHA4 (66%), and PLS3 (66%); and down-regulation of STAT4 (91%). Loss of CD26 (≥80% CD4(+) T cells) and/or CD7 (≥40% CD4(+) T cells) and combination of altered expression of STAT4, TWIST1, and DNM3 or PLS3 could distinguish, respectively, 83% and 98% of patients with S{\'e}zary syndrome from patients with erythrodermic inflammatory dermatoses with 100% specificity. These additional diagnostic panels will be useful adjuncts in the differential diagnosis of S{\'e}zary syndrome versus erythrodermic inflammatory dermatoses.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers/analysis, CD4-Positive T-Lymphocytes/cytology, Diagnosis, Differential, Europe, Female, Flow Cytometry, Gene Dosage, Gene Expression Profiling, Gene Expression Regulation, Humans, Immunophenotyping/standards, Inflammation, Male, Middle Aged, Polymerase Chain Reaction, Reproducibility of Results, Sensitivity and Specificity, Sezary Syndrome/diagnosis, Skin Diseases/diagnosis",
author = "Boonk, {Stephanie E} and Zoutman, {Willem H} and Anne Marie-Cardine and {van der Fits}, Leslie and Out-Luiting, {Jacoba J} and Mitchell, {Tracey J} and Isabella Tosi and Morris, {Stephen L} and Blaithin Moriarty and Nina Booken and Moritz Felcht and Pietro Quaglino and Renata Ponti and Emanuela Barberio and Caroline Ram-Wolff and Kirsi J{\"a}ntti and Annamari Ranki and Bernengo, {Maria Grazia} and Claus-Detlev Klemke and Armand Bensussan and Laurence Michel and Sean Whittaker and Martine Bagot and Tensen, {Cornelis P} and Rein Willemze and Vermeer, {Maarten H}",
note = "Copyright {\textcopyright} 2016 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = jul,
doi = "10.1016/j.jid.2016.01.038",
language = "English",
volume = "136",
pages = "1364--1372",
journal = "J INVEST DERMATOL",
issn = "0022-202X",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures

T2 - A Multicenter Study of 59 Patients

AU - Boonk, Stephanie E

AU - Zoutman, Willem H

AU - Marie-Cardine, Anne

AU - van der Fits, Leslie

AU - Out-Luiting, Jacoba J

AU - Mitchell, Tracey J

AU - Tosi, Isabella

AU - Morris, Stephen L

AU - Moriarty, Blaithin

AU - Booken, Nina

AU - Felcht, Moritz

AU - Quaglino, Pietro

AU - Ponti, Renata

AU - Barberio, Emanuela

AU - Ram-Wolff, Caroline

AU - Jäntti, Kirsi

AU - Ranki, Annamari

AU - Bernengo, Maria Grazia

AU - Klemke, Claus-Detlev

AU - Bensussan, Armand

AU - Michel, Laurence

AU - Whittaker, Sean

AU - Bagot, Martine

AU - Tensen, Cornelis P

AU - Willemze, Rein

AU - Vermeer, Maarten H

N1 - Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2016/7

Y1 - 2016/7

N2 - Differentiation between Sézary syndrome and erythrodermic inflammatory dermatoses can be challenging, and a number of studies have attempted to identify characteristic immunophenotypic changes and molecular biomarkers in Sézary cells that could be useful as additional diagnostic criteria. In this European multicenter study, the sensitivity and specificity of these immunophenotypic and recently proposed but unconfirmed molecular biomarkers in Sézary syndrome were investigated. Peripheral blood CD4(+) T cells from 59 patients with Sézary syndrome and 19 patients with erythrodermic inflammatory dermatoses were analyzed for cell surface proteins by flow cytometry and for copy number alterations and differential gene expression using custom-made quantitative PCR plates. Experiments were performed in duplicate in two independent centers using standard operating procedures with almost identical results. Sézary cells showed MYC gain (40%) and MNT loss (66%); up-regulation of DNM3 (75%), TWIST1 (69%), EPHA4 (66%), and PLS3 (66%); and down-regulation of STAT4 (91%). Loss of CD26 (≥80% CD4(+) T cells) and/or CD7 (≥40% CD4(+) T cells) and combination of altered expression of STAT4, TWIST1, and DNM3 or PLS3 could distinguish, respectively, 83% and 98% of patients with Sézary syndrome from patients with erythrodermic inflammatory dermatoses with 100% specificity. These additional diagnostic panels will be useful adjuncts in the differential diagnosis of Sézary syndrome versus erythrodermic inflammatory dermatoses.

AB - Differentiation between Sézary syndrome and erythrodermic inflammatory dermatoses can be challenging, and a number of studies have attempted to identify characteristic immunophenotypic changes and molecular biomarkers in Sézary cells that could be useful as additional diagnostic criteria. In this European multicenter study, the sensitivity and specificity of these immunophenotypic and recently proposed but unconfirmed molecular biomarkers in Sézary syndrome were investigated. Peripheral blood CD4(+) T cells from 59 patients with Sézary syndrome and 19 patients with erythrodermic inflammatory dermatoses were analyzed for cell surface proteins by flow cytometry and for copy number alterations and differential gene expression using custom-made quantitative PCR plates. Experiments were performed in duplicate in two independent centers using standard operating procedures with almost identical results. Sézary cells showed MYC gain (40%) and MNT loss (66%); up-regulation of DNM3 (75%), TWIST1 (69%), EPHA4 (66%), and PLS3 (66%); and down-regulation of STAT4 (91%). Loss of CD26 (≥80% CD4(+) T cells) and/or CD7 (≥40% CD4(+) T cells) and combination of altered expression of STAT4, TWIST1, and DNM3 or PLS3 could distinguish, respectively, 83% and 98% of patients with Sézary syndrome from patients with erythrodermic inflammatory dermatoses with 100% specificity. These additional diagnostic panels will be useful adjuncts in the differential diagnosis of Sézary syndrome versus erythrodermic inflammatory dermatoses.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers/analysis

KW - CD4-Positive T-Lymphocytes/cytology

KW - Diagnosis, Differential

KW - Europe

KW - Female

KW - Flow Cytometry

KW - Gene Dosage

KW - Gene Expression Profiling

KW - Gene Expression Regulation

KW - Humans

KW - Immunophenotyping/standards

KW - Inflammation

KW - Male

KW - Middle Aged

KW - Polymerase Chain Reaction

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Sezary Syndrome/diagnosis

KW - Skin Diseases/diagnosis

U2 - 10.1016/j.jid.2016.01.038

DO - 10.1016/j.jid.2016.01.038

M3 - SCORING: Journal article

C2 - 26930587

VL - 136

SP - 1364

EP - 1372

JO - J INVEST DERMATOL

JF - J INVEST DERMATOL

SN - 0022-202X

IS - 7

ER -